Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Debt (2020 - 2022)

Anika Therapeutics has reported Total Debt over the past 7 years, most recently at $4.3 million for Q2 2022.

  • Quarterly Total Debt fell 74.42% to $4.3 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Jun 2022, down 74.42% year-over-year, with the annual reading at $4.3 million for FY2021, 67.04% down from the prior year.
  • Total Debt was $4.3 million for Q2 2022 at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $50.0 million in Q2 2020 and troughed at $4.3 million in Q3 2021.
  • The 3-year median for Total Debt is $13.1 million (2020), against an average of $16.3 million.
  • The largest YoY upside for Total Debt was 66.26% in 2021 against a maximum downside of 82.8% in 2021.
  • A 3-year view of Total Debt shows it stood at $13.1 million in 2020, then plummeted by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Total Debt are $4.3 million (Q2 2022), $4.3 million (Q1 2022), and $4.3 million (Q4 2021).